• It has been proposed that a PrP pathogenic mechanism is

  2023-04-11

  

  It has been proposed that a PrP pathogenic mechanism is a toxic gain of function secondary to the misfolding of mutated PrP. However, such a mechanism might not apply to all mutant PrP species, since some mutations had little effect on the stability and folding kinetics of PrP (Swietnicki et al., 19

• br Angiogenesis as a critical event in

  2023-04-11

  

  Angiogenesis as a critical event in diabetic retinopathy Angiogenesis refers to the abnormal proliferation of blood vessels during various pathological conditions. It acquires the stature of being one of the most detrimental events responsible for the progression of diabetic retinopathy. Angiogen

• Previous studies have thus demonstrated that AR activation

  2023-04-11

  

  Previous studies have thus demonstrated that AR activation generally correlates with the promotion of urothelial carcinogenesis and cancer growth. In this article, we review available data suggesting their modulation through the AR pathway as well as correlations of AR signals with sensitivity to co

• Dose Response Studies Against Puromycin

  2023-04-10

  

  Dose–Response Studies Against Puromycin–Sensitive Aminopeptidase (PSA). PSA is a ubiquitous metallopeptidase encoded by the NPEPPS gene with subcellular distribution in the cytosol and nucleus [49]. Comprising of a 919 amino WWL 70 synthesis sequence, it has a broad substrate specificity, and is re

• br Introduction The structural similarities

  2023-04-10

  

  Introduction The structural similarities between puromycin (1, Fig. 1) and the aminoacyl adenyl terminal of aminoacyl–tRNA allow it to terminate the protein synthesis process by causing premature release of a polypeptide from the ribosome [1], [2]. Tremendous progress in the study of puromycin an

• It was also shown that of

  2023-04-10

  

  It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation

• ALK fusion positive NSCLC is clinically

  2023-04-10

  

  ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective

• br Materials and methods br

  2023-04-10

  

  Materials and methods Results Discussion Several major signaling and developmental pathways (e.g. EGFR, ALK, KRAS, TGFβ, Notch and Wnt/β-catenin) have been shown to be involved in lung carcinogenesis and they are being exploited as targets of the non-small cell lung cancer therapy (for revi

• Despite these efforts to prevent

  2023-04-10

  

  Despite these efforts to prevent oxidative metabolic degradation, and showed only marginal improvements in metabolic stability and still exhibited high plasma clearances as shown in . High molecular weight as well as relative high log values could be contributing factors to the poor PK profiles of

• A high throughput small molecule ACK biochemical inhibition

  2023-04-10

  

  A high-throughput small molecule ACK1 biochemical inhibition screen was performed in-house and led to the identification of 1μM inhibitor furanopyrimidine (). Further binding studies found Ivacaftor benzenesulfonate synthesis to be both ATP-competitive and reversible. Early structure-activity rel

• br Acknowledgements This work is sponsored by the National N

  2023-04-10

  

  Acknowledgements This work is sponsored by the National Natural Science Foundation of China (grant no. 31201963) and Youth Backbone Teachers Project in Henan Province Department of Education, China (grant no. 2016GGJS-061). Introduction Acute lymphoblastic leukemia (ALL) is a malignant disord

• br Antiangiogenic therapy in non small cell lung cancer

  2023-04-10

  

  Antiangiogenic therapy in non-small cell lung cancer (NSCLC) Antiangiogenic targeted therapy is an area of active research in which numerous agents have been studied and have been shown to be effective for many tumor types including NSCLC. Angiogenesis is frequently upregulated in malignant solid

• Oxaliplatin For all three fluorescent dyes used

  2023-04-10

  

  For all three fluorescent dyes used, the double-labeled UQ-bodies showed higher antigen responses. A plausible mechanism for the higher quenching observed for the double-labeled UQ-bodies is the dye-dye quenching due to H-dimer formation [19] between the two dyes introduced into the Fd and L chains.

• br The lipoxygenase pathway in diseases of

  2023-04-10

  

  The 12/15-lipoxygenase pathway in diseases of the nervous system Conclusions and future perspectives Arachidonic Ac-DEVD-pNA receptor and other polyunsaturated fatty acids, and their lipid metabolites, play very important roles in human health and disease. This review has outlined the function

• br Discussion Here we show opposing effects of

  2023-04-07

  

  Discussion Here, we show opposing effects of iontophoretically administered phenylephrine,aselective α1-AR agonist, on firing of putatively DAergic and non-DAergic neurons recorded in vivo in the VTA of urethane anaesthetized rats. Phenylephrine application caused a relatively weak decrease in fi

13968 records 255/932 page Previous Next First page 上5页 251252253254255 下5页 Last page